Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia

BACKGROUND: Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) have limited treatment options. Ceralasertib, a selective ataxia telangiectasia and Rad-3-related protein (ATR) inhibitor, demonstrated synergistic preclinical activity with a Bruton tyrosine kinase (BTK) inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Jurczak, Wojciech, Elmusharaf, Nagah, Fox, Christopher P., Townsend, William, Paulovich, Amanda G., Whiteaker, Jeffrey R., Krantz, Fanny, Wun, Chuan-Chuan, Parr, Graeme, Sharma, Shringi, Munugalavadla, Veerendra, Manwani, Richa, Dean, Emma, Munir, Talha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233611/
https://www.ncbi.nlm.nih.gov/pubmed/37273420
http://dx.doi.org/10.1177/20406207231173489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233611/
https://www.ncbi.nlm.nih.gov/pubmed/37273420
http://dx.doi.org/10.1177/20406207231173489

Ejemplares similares